Pfizer Inc. $PFE Shares Bought by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 22.5% in the second quarter, Holdings Channel.com reports. The fund owned 255,629 shares of the biopharmaceutical company’s stock after purchasing an additional 46,984 shares during the period. J.W. Cole Advisors Inc.’s holdings in Pfizer were worth $6,196,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $27,000. Curio Wealth LLC raised its holdings in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new position in Pfizer during the 2nd quarter valued at about $29,000. Finally, Evelyn Partners Asset Management Ltd purchased a new stake in Pfizer during the second quarter worth about $33,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PFE. Guggenheim raised their price objective on shares of Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Scotiabank began coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.39.

Pfizer Price Performance

Pfizer stock opened at $25.73 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $24.91 and a 200-day simple moving average of $24.54. The stock has a market cap of $146.26 billion, a P/E ratio of 13.68, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.